|
Jan 10
|
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
|
|
Jan 4
|
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
|
|
Dec 19
|
Aclaris Therapeutics Provides Corporate Update
|
|
Dec 5
|
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
|
|
Dec 4
|
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Nov 16
|
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
|
|
Nov 14
|
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
|
|
Nov 13
|
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
|
|
Nov 11
|
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
|
|
Nov 6
|
Aclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial Results
|
|
Nov 6
|
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
|
|
Aug 10
|
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
|
|
Aug 8
|
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11%
|
|
Aug 7
|
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 7
|
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
|
|
Apr 27
|
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
|
|
Apr 24
|
3 Biotech Stocks to Sell Before They’re 6 Feet Under
|